Endologix Announces that Scott Huennekens Joins Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that R. Scott Huennekens has been appointed to the Endologix Board of Directors.

Mr. Huennekens is a highly regarded medtech CEO, chairperson, entrepreneur and investor, serving an impressive list of companies. Previously, he led Volcano Corp. (VOLC), a leader in minimally invasive therapy guidance in interventional cardiology, from start-up in 2002 to IPO to its sale to Philips in 2015. He was awarded E&Y’s entrepreneur of the year award in 2010 and was recognized by Goldman Sachs in 2016, 2017, & 2018 as one of the 100 most intriguing entrepreneurs at its annual Builders & Innovators conference. Mr. Huennekens graduated magna cum laude with a BS in Business Administration from the University of Southern California and holds his MBA from the Harvard Business School.

“We are delighted to announce Scott Huennekens as the newest member of our board. With Scott’s extensive background in med-tech as both an operator and board adviser, he will be a valuable asset to the company as we go forward," expressed John Liddicoat, MD, President and CEO of Endologix.

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR™ System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com.